Summary of Purpose
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 18 July 2017.
|15 Aug 2017||14 Jul 2017||15 Aug 2019||31 Dec 2019||1 Jul 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Doylestown Health Lead
- Sudhir Aggarwal, MD, PhD